'Nano-Anesthesia': A New Approach to Local Anesthesia?
Magnet-Directed Nanoparticles with Local Anesthetic Produce Effective Nerve Block in Rats
Article ID: 616382
Released: 11-Apr-2014 11:00 AM EDT
Source Newsroom: Wolters Kluwer Health: Lippincott Williams and Wilkins
Newswise — San Francisco, CA. (April 11, 2014) – A technique using anesthesia-containing nanoparticles—drawn to the targeted area of the body by magnets—could one day provide a useful alternative to nerve block for local anesthesia in patients, suggests an experimental study in the April issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
"We have established proof of principle that it is possible to produce ankle block in the rat by intravenous injection of magnetic nanoparticles associated with ropivacaine and magnet application at the ankle," write Dr Venkat R.R. Mantha and colleagues of University of Pittsburgh School of Medicine. With further study, the nano-anesthesia technique might allow more potent doses of local anesthetics to be delivered safely during local anesthesia in humans.
Magnets Used to Attract Anesthesia-Containing NanoparticlesThe experimental pilot study evaluated the use of magnet-directed nanoparticles containing the local anesthetic drug ropivacaine (MNP/Ropiv) to produce anesthesia of the limbs. The researchers engineered nanoparticle complexes containing small amounts of ropivacaine and the iron oxide mineral magnetite. The MNP/Ropiv complexes were injected into the veins (intravenously, or IV) of anesthetized rats.
The researchers then placed magnets around the ankle of the right paw for 15, 30, or 60 minutes. The goal was to use the magnets to draw the nanoparticles to ankle. Once there, the particles would release the anesthetic, numbing the nerves around the ankle.
Sensation in the right paw was assessed by comparing the right paw to the left paw, which was not affected. Other groups of rats received standard nerve block, with ropivacaine injected directly into the ankle; or IV injection of ropivacaine alone, not incorporated into nanoparticles.
Injection of MNP/Ropiv complexes followed by magnet application produced significant nerve block in the right ankle, similar to a standard nerve block. The left ankle was unaffected.
Nano-Anesthesia Could Permit Safe Use of Higher Anesthetic Drug DosesThe ankle block produced by MNP/Ropiv injection was greatest when the magnet was applied for 30 minutes—likely reflecting the time of maximum ropivacaine release. High ropivacaine concentrations were found in right ankles of the MNP/Ropiv group, suggesting "sequestration of the drug locally by the magnet."
In rats receiving MNP/Ropiv, the nanoparticles contained a total of 14 milligrams of ropivacaine—a dose high enough to cause potentially fatal toxic effects. Yet none of the animals in the MNP/Ropiv group had apparent adverse effects of ropivacaine. This was similar to the findings in rats receiving 1 milligram of plain ropivacaine. Thus the safe dose of ropivacaine combined with nanoparticles could be at least 14 times higher, compared to IV ropivacaine alone.
Magnet-directed nanoparticles have previously been used for targeted delivery of chemotherapy drugs. The new study suggests that a similar technique could be used to attract local anesthetic-containing nanoparticles to specific areas, as an alternative to local anesthetic block—like that used for foot and ankle surgery, for example.
Additional animal experiments would be needed before the MNP/Ropiv technique can be tested in humans. But if it proved safe, the magnet-directed approach could provide a useful new alternative for regional anesthesia—delivering high concentrations of local anesthetics directly to the desired area, without increasing toxic effects.
About Anesthesia & AnalgesiaAnesthesia & Analgesia was founded in 1922 and was issued bi-monthly until 1980, when it became a monthly publication. A&A is the leading journal for anesthesia clinicians and researchers and includes more than 500 articles annually in all areas related to anesthesia and analgesia, such as cardiovascular anesthesiology, patient safety, anesthetic pharmacology, and pain management. The journal is published on behalf of the IARS by Lippincott Williams & Wilkins (LWW), a division of Wolters Kluwer Health.
About the IARSThe International Anesthesia Research Society is a nonpolitical, not-for-profit medical society founded in 1922 to advance and support scientific research and education related to anesthesia, and to improve patient care through basic research. The IARS contributes nearly $1 million annually to fund anesthesia research; provides a forum for anesthesiology leaders to share information and ideas; maintains a worldwide membership of more than 15,000 physicians, physician residents, and others with doctoral degrees, as well as health professionals in anesthesia related practice; sponsors the SmartTots initiative in partnership with the FDA; and publishes the monthly journal Anesthesia & Analgesia in print and online.
About Wolters Kluwer HealthWolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries worldwide, clinicians rely on Wolters Kluwer Health’s market leading information-enabled tools and software solutions throughout their professional careers from training to research to practice. Major brands include Health Language®, Lexicomp®, Lippincott Williams & Wilkins, Medicom®, Medi-Span®, Medknow, Ovid®, Pharmacy OneSource®, ProVation® Medical and UpToDate®.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2013 annual revenues of €3.6 billion (US$4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Follow our official Twitter handle: @WKHealth.